Clinical Trial

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Study acronym: TNT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2019-03-20; most recent amendment 2025-02-21.
Status change: Not Yet Recruiting → Recruiting 2019-05-16
Trial Details
NCT Number NCT03886311
Lead Sponsor Sarcoma Oncology Research Center, LLC
Conditions Sarcoma
Enrollment 200 participants
Start Date 2019-05-15
Primary Completion 2030-12-31 (estimated)
Study Completion 2031-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-24